Biomedical subjects
Publications and source records attributed to M T Swartz.
The current status of mechanical circulatory support in patients with cardiogenic shock is presented in terms of patient and device selection. Advantages of the complications associated with this type of therapy is discussed.
Levels of T lymphocytes were measured in 20 consecutive patients, 18 men and two women, supported with ventricular assist devices or an artificial heart. Indications for support were bridge to transplantation (n = 10), postcardiotomy cardiogenic shock (n = 8), and acute myocardial infarction shock (n = 2). Control levels were from healthy volunteers not undergoing cardiac operation. Preoperatively, numbers of total lymphocytes and subclasses CD3, CD4, and CD8, as well as the interleukin-2 receptors (IL2R), were the same as controls (cells/microliters): lymphocytes, 1,940; CD3, 1,413 +/- 410; CD4, 894 +/- 318; CD8, 490 +/- 185; IL2R, 96. From implant to postoperative day 5, levels were below control values (p less than 0.001), reaching a nadir on postoperative day 2 (lymphocytes, 896 +/- 599; CD3, 489 +/- 267; CD4, 309 +/- 207; CD8, 183 +/- 107; IL2R, 43 +/- 47). Data from 10 patients (group 1) who survived (four weaned from cardiopulmonary bypass, six transplanted) were compared with those from 10 patients (group 2) who died of multiorgan failure, sepsis, or both. From preimplant through postoperative day 6, levels did not differ between groups. However, from postoperative day 7 to the last day of ventricular support (group 1, 24-90 days; group 2, 7-29 days), group 1 levels (lymphocytes, 2,364 +/- 618; CD3, 1,825 +/- 553; CD4, 1,013 +/- 187; CD8, 796 +/- 402) were significantly above (p less than 0.01) group 2 levels (lymphocytes, 1,290 +/- 463; CD3, 746 +/- 295; CD4, 534 +/- 253; CD8, 221 +/- 106). These data indicate that lymphocytes and particularly T cells 1) decrease after ventricular assist device insertion, reaching a nadir at postoperative day 2, 2) return to control values after patients whose clinical status improves, and 3) remain low in severely ill patients. T-cell depression in ventricular assist device patients is related to the severity of the patient's condition rather than the presence of the device.
A multidisciplinary approach to circulatory support is discussed in this article. The clinical, educational, and investigational responsibilities of each team member are presented.
As cardiac transplantation becomes more commonplace in the treatment of end-stage heart failure and as suitable donors become less available, an increasing number of patients will require mechanical circulatory assistance to bridge to transplantation. Since 1982, refractory hemodynamic instability requiring placement of pulsatile ventricular assist devices (VADs) has developed in 11 candidates for transplantation aged 24 to 54 years (mean, 39.6 years). A pneumatic Pierce-Donachy pump was used in 9 patients and an electrical Novacor pump in 2. The cause of the cardiomyopathy was ischemic in 6, postpartum in 2, idiopathic in 2, and doxorubicin hydrochloride toxicity in 1. Seven patients required left ventricular support (LVAD); 4 required biventricular mechanical support (BVAD). Duration of support ranged from 8 hours to 91 days with flows ranging from 4.1 to 8.5 L/min (mean, 5.5 L/min). Although hemodynamic stability was achieved in all 11 patients, contraindications to transplantation developed in 5 patients during VAD support (renal failure in 4, sepsis in 3, disseminated intravascular coagulopathy in 1). The remaining 6 patients (4 with an LVAD, 2 with a BVAD) remained good candidates for transplantation despite major complications in 5 (mediastinal bleeding in 3, driveline infection in 3, development of preformed antibodies in 2, small embolic stroke caused by device malfunction in 1). The 3 patients who were supported the longest (24, 75, and 91 days) were ambulatory while awaiting a donor heart. All 6 patients underwent successful transplantation after 8 hours to 91 days (mean, 24 days) of support. Other than one sternal wound infection, there were no major complications after transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)
Ventricular-assist devices (VAD) have increased survival in patients with postcardiotomy shock, but the predictors of success need to be elucidated. We evaluated 45 patients treated with centrifugal (n = 18) or pulsatile (n = 27) VAD for postcardiotomy cardiogenic shock to determine the effect of perioperative myocardial infarction (PMI) on survival. The patients ranged in age from 15 to 72 years (mean age, 55.1 years). VAD support was left ventricular in 29, right ventricular in seven, and biventricular in nine, and the flow-rate range was 1.6-5.2 l/min (mean rate, 3.97 l/min) for 0.2-22 days (mean time, 4.1 days). PMI was determined by analysis of postoperative electrocardiogram (EKG), enzyme levels, or at necropsy. PMI was considered "possible" if there were either EKG or enzyme level changes, and "definite" if there were EKG and enzyme level changes or necropsy evidence. Of the 45 patients, 19 were successfully weaned from ventricular assistance; 12 were discharged (Group 1), and seven died (Group 2); the remaining 26 patients could not be weaned from VAD support (Group 3). In Group 1, one patient had a definite PMI, and three had a possible PMI. Among the 33 nonsurvivors (Groups 2 and 3), 24 patients had PMI by necropsy examination. Definite PMI was much more common in nonsurvivors (72.7%) than in survivors (8.3%) (p less than 0.05). However, Group 2 nonsurvivors were weaned despite PMI in 100% of cases. These data suggest that, although PMI is a strong negative determinant of survival in postcardiotomy patients, it cannot be considered a contraindication because it does not preclude myocardial recovery.
Improvements in mechanical support for profound circulatory collapse have resulted in increasing survival of these critically ill patients. Since 1980, 27 patients aged 3 days to 69 years (mean 34.9 years) who required mechanical circulatory assistance have been followed up after discharge from the hospital. The refractory cardiogenic shock necessitating mechanical support occurred postoperatively in 22 patients (coronary artery bypass in nine, valve replacement in four, correction of congenital heart defects in nine) and with end-stage cardiomyopathy in five. Fourteen patients were supported with a Pierce-Donachy ventricular assist device (left ventricular assist in seven, right ventricular assist in three, both in four); nine were supported with extracorporeal membrane oxygenation, two with a Medtronic centrifugal left ventricular assist pump, one with biventricular Biomedicus pumps, and one with a Novacor left ventricular assist system. The duration of support ranged from 8 hours to 91 days with a mean of 3.5 days in patients supported for postoperative shock. Major complications occurred in 18 patients (67%), including bleeding that necessitated operative exploration in 14, serious infection in five, renal failure in two, and stroke in two. The five patients with cardiomyopathy underwent cardiac transplantation. The remaining 22 patients who had postoperative cardiogenic shock were weaned from support. There have been four late deaths: two cardiac related at 6 months and two of cancer at 46 and 53 months (one patient was in New York Heart Association class I and the other in class II before death). The remaining 23 survivors have been followed up for 3 to 79 months (mean 29 months) and at last examination 17 (74%) were in class I, two (9%) were in class II, three (13%) were in class III, and one (4%) was in class IV. Eight patients are employed full time, three are retired, four attend school, three are in preschool, one is a housewife, and one is unemployed but free of symptoms. Only four patients have significant cardiac disability, and one of these still works. In conclusion, mechanical circulatory assistance allows adequate support to permit satisfactory long-term survival in patients with refractory cardiogenic shock.
Recent technologic advances have led to the development of safe and effective mechanical ventricular assist devices for clinical use. Pneumatic assist devices are being used at an increasing rate at a limited number of institutions throughout the country. One of the major factors in influencing survival of these critically ill patients is establishing standards of nursing care. We recently reviewed our experience of 41 patients who received a Pierce-Donachy ventricular assist device to evaluate the effectiveness of nursing care being provided to these patients. This article includes our most recent protocols of nursing care, which have evolved over the past 6 years. Nursing interventions to prevent or treat common complications such as bleeding, renal failure, and infection are discussed.
Diltiazem was evaluated as an adjunct to cold blood potassium cardioplegia in 63 patients undergoing elective coronary artery bypass grafting. The dual-phase study compared incrementally increasing doses (50, 100, and 150 micrograms/kg) of diltiazem using a single-blind, randomized schedule with an equivalent volume of placebo added to each of three infusions of cold (10 degrees C +/- 2 degrees C) blood containing potassium chloride at 25 mEq/L for the initial infusion (400 ml) and at 12 mEq/L for the next two infusions (300 ml each). Observations included a number of operative variables, creatine kinase (CK)-MB curves, two-dimensional echocardiography, and pulsed Doppler sonography before operation and on postoperative days 1 and 5. Pulmonary artery thermistor catheter responses were observed for 16 hours postoperatively, as were left ventricular micromanometer-tipped catheter responses in 7 patients. As the dose of diltiazem was increased, there was increasing time to atrioventricular node refunction (23.6 to 62.0 minutes). Diltiazem at 100 micrograms/kg (D-100) resulted in a significantly lower peak CK-MB activity than its placebo. Peak - dp/dt increased in treated patients and decreased in patients given the placebo. The cardiac index in D-100 patients was greater on the first postoperative day than preoperatively. The stroke index returned to the control level by the fifth postoperative day in D-50 and D-100 patients only, and it remained depressed in placebo patients. Although few benefits were realized from the addition of diltiazem to cold blood potassium cardioplegia, there was dose-related prolongation of the atrioventricular node recovery time, which required cardiac pacing and thus was associated with its attendant risks.
Explore the source record for details and available documents.
From 1962 to mid-1984, 63 infants underwent coarctation repair. Cardiac defects were present in 46 (73%). Repair was by subclavian aortoplasty in 35 patients, resection and end-to-end anastomosis in 19, and other techniques in 6. Three patients died before the repair was completed. In 15 patients, an intraluminal shunt was used during subclavian aortoplasty. Prostaglandin E1 (PGE1) was infused in 9 patients. Early (thirty-day) mortality was 16% (10 patients): 4 patients who underwent end-to-end anastomosis; 3 during attempted end-to-end anastomosis; 2 who received bypass grafts; and 1 who had subclavian aortoplasty without a shunt. None of the 15 patients who had subclavian aortoplasty with a shunt died. There were no early deaths among the last 25 patients seen. One patient who underwent subclavian aortoplasty without a shunt is paraplegic. There were 10 late deaths among the 53 patients followed from 1 month to 12 years (mean, 3 years). Arm-leg pressure gradients of 20 mm Hg or greater were found in 4 of the patients who had end-to-end anastomosis but not in any of the patients who had subclavian aortoplasty. Improved results of coarctation repair in infants in this study were attributed to PGE1, subclavian aortoplasty, and use of an intraluminal shunt.
To evaluate the importance of severe biventricular failure in patients with postcardiotomy ventricular failure, we analyzed the data from 30 patients treated with ventricular assist devices (VADs) over a five-year period. All patients had profound postoperative ventricular failure refractory to drugs and an intraaortic balloon (IAB). Evaluation of preoperative ventricular function did not allow prediction of which patients would require VADs. However, the development of perioperative myocardial infarction was an important determinant of the need for postoperative support with a VAD. Twenty patients received only a left VAD (LVAD). Four of them had isolated left ventricular failure; 3 were weaned, and 2 survived. None of the 16 patients with biventricular failure who received only an LVAD were weaned. Ten other patients with biventricular failure received biventricular support, either with a right VAD and IAB, or with two VADs. Of these 10 patients, 5 were weaned and 3 survived. Considering all 26 patients with biventricular failure, those receiving biventricular mechanical support (10) had a better chance (p less than 0.025) of being weaned (5/10) and surviving (3/10) than those who received only an LVAD (0/16). We conclude that biventricular failure is common in patients with postcardiotomy ventricular failure and is often the result of perioperative infarction. While patients with isolated left ventricular failure did well with an LVAD only, those with biventricular failure required biventricular mechanical support for survival.
Explore the source record for details and available documents.
From January, 1972, through August, 1977, 472 patients had internal mammary artery (IMA) coronary bypass, of which 100 were double-IMA bypasses. We selected those patients having a widely patent IMA one year postoperatively who then had a second catheterization 49 to 105 (mean, 64) months following operation. None of the 93 patients who met these criteria was specifically recalled for this study; they all had follow-up catheterizations for multiple other reasons. All of the 91 left IMA and 22 right IMA bypasses (total, 113) were patent at late catheterization, but 1 right IMA was diffusely narrowed. One left IMA had acute angulation with 50% stenosis proximal to the distal anastomosis, which was unchanged over the follow-up interval. There were 100 patent saphenous vein bypasses at one year and 87 at late catheterization. Late closure of coronary bypass grafts is secondary to progression of coronary disease, atherosclerosis of the bypass conduit, or intimal proliferation. Because we have not encountered the latter two causes of conduit closure, IMA grafts remain our graft of choice for nonemergent operations in patients under 60 years of age having revascularization of the left anterior descending coronary artery system.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Impedance reduction with a continuous infusion of hydralazine was evaluated in 20 patients following cardiopulmonary bypass. Patients were selected for therapy when the cardiac index (CI) was less than 2.2 L/m2/min, when the systemic vascular resistance index (SVRI) was greater than 2,500 dyne sec cm-5, or when both conditions were present. No other vasoactive or cardiotonic drugs were used intraoperatively or postoperatively. Responses were measured at 15, 30, 60, 120, 180, and 240 minutes and compared with control measurements. Significant responses appeared by 15 minutes in the mean arterial pressure, CI, and SVRI, which were maximal by 2 hours. At 4 hours, the SVRI was 1,520 +/- 276 dyne sec cm-5 (control, 3,235 +/- 222) and pulmonary vascular resistance index, 365 +/- 102 dyne sec cm-5 (control, 592 +/- 71). The CI was 3.20 +/- 0.29 L/m2/min (control, 1.96 +/- 0.16) and mean arterial pressure, 75 +/- 2.3 mm Hg (control, 92 +/- 2.4). Left atrial, pulmonary artery diastolic, and right atrial pressures increased from control but not significantly: 11.4 +/- 0.8 to 13.3 +/- 1.2 mm Hg, 13.6 +/- 1.6 to 17.2 +/- 1.5 mm Hg, and 6 +/- 1.6 to 9.4 +/- 1.7 mm Hg, respectively. In 16 patients, hydralazine was continued for 24 hours and in 11, the transition to oral therapy was made. Hydralazine by infusion effectively reduces after load, avoids the fluctuations of bolus therapy, and allows the transition to oral therapy if needed.
Although it is now possible to obtain, with mechanical circulatory support devices, survival of postcardiotomy patients who develop profound cardiogenic shock, their long-term functional status has not been firmly established. We studied 22 patients who survived cardiac operations by the use of circulatory support devices. Their ages ranged from 3 days to 69 years at the time of device support. Operations performed were coronary artery bypass (9 pts), valve replacement (4 pts), congenital defect correction (8 pts), and cardiac transplantation (1 pt). Ten patients were supported with a Pierce-Donachy ventricular assist device (VAD) (left 4, right 3, both 3), nine with extracorporeal membrane oxygenation (ECMO), and three with centrifugal pumps (left 2, both 1). Duration of support ranged from 22 to 189 hours (mean 84.4). There were four late deaths; two of the deaths were cardiac-related within 6 months and two were due to cancer at 46 and 53 months following discharge. The remaining 18 survivors were followed for 6 to 74 months (mean 29.9). Prior to operation three of the patients were New York Heart Association (NYHA) Class I, eight were Class II, six patients were Class III, and five were Class IV. Following discharge from the hospital 13 patients were Class I, two were Class II, and three were Class III; no patients were Class IV. Five patients work full-time, three are retired without limitation, four attend school, and three are pre-school. Only three patients suffer from moderate cardiac disability. These data suggest that patients surviving mechanical circulatory assistance for postoperative cardiogenic shock have an excellent chance for functional recovery.
In order to determine if hemodynamic parameters can accurately predict whether patients can be successfully weaned from ventricular assists devices (VADs), we studied 24 patients supported with Pierce-Donachy VADs (11 left VAD; 6 right VAD; 7 biventricular VAD) following cardiogenic shock for periods from 1.3 to 22 days (mean 5.4). Myocardial recovery was determined by daily measurements of "pump on/pump off" parameters, and the data from seven LVAD patients (64%) and three RVAD patients (50%) whose hearts recovered were compared to the data from those whose did not. Additionally, data from the five patients (71%) weaned from biventricular support were compared to those weaned from only a single LVAD or RVAD. In this study, daily pump on/pump off hemodynamic measurements were found to be predictive of success for weaning patients from VADs. The most significant predictors were increases in mixed venous oxygen saturation, cardiac index, mean arterial pressure and ventricular ejection fraction, as well as decreases in atrial pressures. Seventy percent of the patients weaned from VADs survived, indicating that patients appropriately weaned from VAD support have a reasonable chance of survival.